Predictive Oncology Earnings Calls
| Release date | May 15, 2026 |
| EPS estimate | - |
| EPS actual | -$0.360 |
| Revenue estimate | - |
| Revenue actual | 35.311K |
| Release date | Mar 31, 2026 |
| EPS estimate | $0.0090 |
| EPS actual | $1.15 |
| EPS Surprise | 12,645.56% |
| Revenue estimate | 5M |
| Revenue actual | 8.674K |
| Revenue Surprise | -99.83% |
| Release date | Nov 14, 2025 |
| EPS estimate | -$1.35 |
| EPS actual | -$4.52 |
| EPS Surprise | -234.81% |
| Revenue estimate | 1.5M |
| Revenue actual | 3.618K |
| Revenue Surprise | -99.76% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$1.35 |
| EPS actual | -$3.30 |
| EPS Surprise | -144.44% |
| Revenue estimate | 1.5M |
| Revenue actual | 2.682K |
| Revenue Surprise | -99.82% |
Last 4 Quarters for Predictive Oncology
Below you can see how AGPU performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $ |
| EPS estimate | -$1.35 |
| EPS actual | -$3.30 |
| EPS surprise | -144.44% |
| Date | Price |
|---|---|
| Nov 13, 2025 | $6.50 |
| Nov 14, 2025 | $6.48 |
| Nov 17, 2025 | $6.08 |
| Nov 18, 2025 | $6.03 |
| 4 days before | -100.00% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | -7.23% |
| Release date | Nov 14, 2025 |
| Price on release | $6.48 |
| EPS estimate | -$1.35 |
| EPS actual | -$4.52 |
| EPS surprise | -234.81% |
| Date | Price |
|---|---|
| Nov 13, 2025 | $6.50 |
| Nov 14, 2025 | $6.48 |
| Nov 17, 2025 | $6.08 |
| Nov 18, 2025 | $6.03 |
| Nov 19, 2025 | $6.22 |
| Nov 20, 2025 | $6.05 |
| 4 days before | -0.308% |
| 4 days after | -6.64% |
| On release day | -6.17% |
| Change in period | -6.92% |
| Release date | Mar 31, 2026 |
| Price on release | $1.62 |
| EPS estimate | $0.0090 |
| EPS actual | $1.15 |
| EPS surprise | 12,645.56% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $1.61 |
| Mar 26, 2026 | $1.48 |
| Mar 27, 2026 | $1.55 |
| Mar 30, 2026 | $1.47 |
| Mar 31, 2026 | $1.62 |
| Apr 01, 2026 | $3.56 |
| Apr 02, 2026 | $4.07 |
| Apr 06, 2026 | $4.25 |
| Apr 07, 2026 | $4.76 |
| 4 days before | 0.621% |
| 4 days after | 193.83% |
| On release day | 119.75% |
| Change in period | 195.65% |
| Release date | May 15, 2026 |
| Price on release | $5.85 |
| EPS estimate | - |
| EPS actual | -$0.360 |
| Date | Price |
|---|---|
| May 11, 2026 | $6.66 |
| May 12, 2026 | $6.66 |
| May 13, 2026 | $6.48 |
| May 14, 2026 | $5.60 |
| May 15, 2026 | $5.85 |
| May 18, 2026 | $4.68 |
| May 19, 2026 | $4.76 |
| May 20, 2026 | $5.13 |
| May 21, 2026 | $5.70 |
| 4 days before | -12.16% |
| 4 days after | -2.56% |
| On release day | -20.00% |
| Change in period | -14.41% |
Predictive Oncology Earnings Call Transcript Summary of Q1 2026
Axe Compute (AGPU) presented Q1 2026 results and an updated go‑forward strategy focused on building and owning GPU clusters deployed inside third‑party data centers. The company operates two customer tracks: (1) immediate access inventory for rapid short‑term needs, and (2) Axe Build long‑term dedicated clusters (3–5 year contracts) that Axe finances, installs, and retains as balance‑sheet assets for redeployment. The company closed a landmark 36‑month, $260 million contract for 2,304 NVIDIA B300s (4.8 MW) in a U.S. Tier 3 data center with targeted deployment in Q3 2026; when live this cluster will drive approximately $21 million of revenue per quarter. Management reports an advanced pipeline of ~45 qualified prospects representing >36,000 GPUs and over $4.3 billion of potential contract value, with a majority of deals trending to 36–60 month terms; the CEO expressed confidence in closing roughly $1 billion of transactions this year. Q1 financials reflect the transitional nature of the business: total revenue was $35k (legacy Drug Discovery declining), net loss $7.7M (largely noncash), cash and equivalents $6.9M, total assets $45.2M, and total equity $40.3M. The CFO emphasized that $4.3M of the Q1 loss was a GAAP mark‑to‑market loss on Aethir token holdings (fair value accounting), which were $20.2M at quarter‑end, and that $15.4M of additional locked tokens are contractual receivables vesting through Dec 2028. Management expects the Axe Build model to generate recurring cash flow and to build owned AI infrastructure assets on the balance sheet that can be redeployed and amortized over shorter equipment lives (3–5 years).
Sign In
Buy AGPU